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Abstract:
The Breakthrough into solid-state research has become emerging ap-
proach for structure determination of Active Pharmaceutical Ingredi-
ents (APIs) and excipeents that consequently influence their physic-
chemical properties, biopharmaceutical and pharmacokinetic profiles. 
The concept of conventional pharmaceutical salts has been extended 
to multicomponent crystals which diversity in nature of the non-
covalent intermolecular interactions determine the crystal packing pat-
terns within the structures, and thus modulate the native properties 
of APIs. Therefore, the aim of this review is to highlight how ac-
complishments in crystallographic research on molecular crystal have 
influenced their classification and how these new solid phases have 
been recognized by the regulatory bodies. The advantage to explore the 
pharmaceutical crystalline solids of one API implies the selection of the 
form with favorable properties for the development of formulations for 
pharmaceutical dosage forms.
Keywords: Crystal structure, non-covalent intermolecular interactions, 
multicomonent crystals, structure-property relationship
1 INTRODUCTION
Significance for research on the pharmaceutical
solid forms
The requirements for investigation new phasesthe solid forms of pharmaceuticals in formsof Active Pharmaceutical Ingrediants (APIs)
and functional excipients, as well testing the sta-
bility of the existing ones has been impelled by
the increasing growth of 5.8% for oral solid dosage
forms (OSD) on the market of contract manufactur-
ing sector through the forecast period of 2017-2028,
generating the revenue of US$ 11.2 Bn in 2019 only
for tablets, within immediate release tablets con-
tribute maximum revenue share. (1) Subsequently,
U.S. Food and Drug Administration (FDA) Center
for drug Evaluation and Research (OCER) ratio in
total approved OSD accounted 53%, 50% and 32%
in 2018, 2017, and 2016 respectively. The advan-
tageous of the OSD pharmaceuticals in terms of
their cost- effectiveness in terms of manufacturing
and handling processes, patient compliant, increased
physical and chemical stability, immediate released
or controlled-release drug biopharmaceutical profil-
ing are directly influenced by the physic-chemical
properties of the selected solid forms of APIs and
IJCRR 11 (11), 20201−20210 MANUSCRIPT CENTRAL 20201
ISSN (O) 0976-4852
The Challenge for Engineering Pharmaceutical Crystalline Solids: Scientific and Regulatory Affairs 
Perspectives for Crystal Structure Design and Prediction
excipients combined in this drug delivery formula-
tions. Approximately 40 % of all drugs with market
approval and 90%drug-candidates in drug discovery
stage exert poor water solubility being categorized
under the Biopharmaceutical Classification System
(BCS) classes II (low solubility and high permeabil-
ity) and IV (low solubility and low permeability). (2,
3)
High R&D cost and time consuming for screening
drug candidates among molecular structures beyond
Lipinski’s the rule of five concept (4), that refers
to high molecular mass, high lipophilicity and hy-
drophobicity (5), as well the declining of drug can-
didates from pipeline, due to poor water solubility,
prompt the drug discovery and development across
the solid form selection in order by optimizing the
physic-chemical properties biopharmaceutical pro-
filing and downstream processing (flowability, par-
ticle size reduction, compacting and etc.) (6) of
APIs conveniently to shortcut the development of
pharmaceutical formulations for solid dosage forms
which are highly share the pharmaceuticals market.
Pharmaceutical Salts (PSs) accounts approximately
50% of the total approved APIs by the U.S. Food and
Drug Administration (FDA) (7), and half of the top
200 prescribed dosage forms in U.S. (8)
Classification of crystalline solids of pharmaceu-
tical relevance: Pharmaceutical Cocrystals vs.
Pharmaceutical Salts
Aside of molecular adducts, inclusion complexes,
solid solution and dispersion, multicomponent crys-
tals of pharmaceutical relevance, depicted on the ,
consider Pharmaceutical Cocrystals (PCCs), Phar-
maceutical Salts (PSs) and Solvates formed by
cocrystallization of at least two component, one
of which API molecule together with neutral con-
former, ion or solvent, respectively as a single phases
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with defined stoichiometric ratio of components (9,
10)Figure 1
The advantage of classification the multicomponent
crystals come out as a consequence of extending the
current list of acceptable counterions for PSs (11),
and more than that toxicologically safe and already
published liquid solvents (12) for solvates, up to
the plentiful of neutral molecules as a coformers
for PCCs, that are solids on ambient conditions and
encompassed to the generally recognized as safe list
(GRAS) and to even broader the everything added
to food in the U.S. list (EAFUS), both regulated by
the U.S. Food & Drug Administration (FDA) (13) in
order counterions, solvents and conformers, each of
them depending on each of their nature (molecular
structure), when cocrystalize with API molecules to
modulate the properties of native API. This con-
ventional scientific approach for classification of
the multicomponent crystals has been recognized
as ambiguous by the academic and industrial com-
munity toward the vibrant debates aiming to con-
tribute the upgrading of the definition for PCCs in
the drafted FDA guidance, the first one issued in
2011 wherein PCCs are dissociable API-excipient
molecular complexes of cocrystallized neutral API
and conformer into solid drug product intermidi-
etes enforcing to comply to the requirements for
current Good manufacturing Practice (cGMP), and
consequently the second another, issued in 2016
that stipulates more comprehensively that PCCs are
redefined as single crystalline materials composed
by cocrystallized molecules of API and non-volatile
conformer, bounded neither by nonionic, nor by
noncovalent interactions, emphasizing that PCCs,
instead of being recognized as the new API, their
new phases to be considered as polymorphs or pseu-
dopolymorphs (hydrates or solvate) of API. (14, 15)
Though both regulatory authorities, US-FDA and
European Medicines Agency (EMA) that are har-
monized in terms of putting in evidence PCCs as
single crystalline materials is a opportunity for dis-
closing the new solid phases of API toward their
novelty, non-obviousness, utility and greenness as
a prerequisite in process of patent protection of the
unique composition and structure of solid state ma-
terial. (16) Furthermore, the variety of conformers
with diverse nature and properties, as a source is
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FIGURE 1: The diversity oforganic solid forms
utilized by crystal engineering that is a tool for
designing crystal with purpose i.e. the conformer to
influence the improvement of the particular and the
desirable property of API, and as well to a cocrystal
as new solid phase, entirely. The principle of co-
crystallization refers to supramolecular chemistry
phenomena of setup noncovalent intermolecular in-
teractions (mainly all type of H-bonding, π•••π
stacking) that, either based on the homomeric molec-
ular recognition between the same molecules, or het-
eromeric recognitions between different ones, such
as API, conformer and solvent, lead to formation the
basic structural units, known as synthons that are
exist as homosynthons and heterosynthons when in
the former the identical functional groups (moieties)
interact by H-bonds and in later when H-bonding
is occurred between different, but complementary
proton donor-acceptor functional groups. (17–19)
Referring to the nature of H-bond as electron donor-
acceptor interactions (20) the charge distribution and
the extent of its transfer indicate to its significant
partial distribution in some molecular crystals that
overlap across both PCCs and PSs, representing
cocrystal-salt continuum. In order to avoid overlap-
ping across the PCs, PSs and Solvates, performed
analyzes of the entries in the Cambridge Structural
Database (CSD), based on the distinguishing charge
location in salts from neutral conformers and sol-
vents, and the number of cocrystallized component
per asymmetric crystal cell (Z), impact the defini-
tions for three classes of PCCs, PSs and Solvates
to be expanded to additional four classes, that are
in total seven mutually exclusive subclasses: true
salt, true solvate, true cocrystal (binary systems, ZR
= 2), salt solvate, cocrystal solvate, cocrystal salts
where naural API cocrystallize with ionic conformer
or salt form of API is cocrystallized with neutral
coformer (ternary systems, ZR = 3), and cocrystal salt
solvate (quaternary systems, ZR = 4), all relevant in
terms of frequency of occurrence. (21) Moreover the
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novelty of multicomponent systems (MCSs) rely on
their appearance in form of the new solid crystalline
phases, the nature of the noncovalent intermolecular
interactions, determined by the molecular structures
of APIs and conformers, and environmental condi-
tions, rule the thermodynamic and kinetic stability
of the solid phases during the opponent processes
of cocrystallization and dissolving. Crystallographic
analyzes performed by both electron and neutron
diffraction, indicated that extend of proton trans-
fer in H-bonds depend on increasing the tempera-
ture. (22, 23) Therefore, X-ray diffraction on low
temperature and cooper radiation on single crystals
elucidate the proton position between the H-bond
lengths formed by different proton doneor/acceptor
groups, such C–O distance that is utile for distin-
guishing PSs from PCCs which components con-
sisted of carboxylic acids. (24) Another approach
for prediction of cocrystal formation, that is con-
tributed by Etther’s hydrogen bond rules (priorities
for best H-bond donor/acceptor pairs) (25), is based
on distinguishing cocrystals from salst and cocrystal
salts based on the ∆pK rule: ∆pK = (∆pKa= [pKa
(conj. base)–pKa (acid)]; ∆pKa≥3 corresponds to
salt formation (26), ∆pKa <0 benchmark for co-
crystal formation, while ∆pKa values 0-3 imply for
continuum of ambiguous prediction in cocrystal salts
formation. (23, 27) Crystal engineering is challeng-
ing concept that utilizes systematic database study
of structural landscape and high throughput crystal
growth screening with crystallographic analyses of
noncovalent interactions and structural parameters as
a variables in determined structures that provide in-
sight in optimizing the crystallization pathways that
are designed strategies both for PCCs and PSs. (28)
Structure – Properties relationship: experimental
vs. crystal structure prediction modeling
Crystal structure prediction (CSP) for PCCs and PSs,
relaying on the quantum mechanical (QM) calcula-
tions for the crystal lattice energy for PCCs and PSs,
indicates that the formation of these multicomponent
crystals is determined by compromising either the
negative enthalpy changes, always in enthalpy driven
formation of PSs, as well in some PCCs and PCC
solvates with entropy changes or positive enthalpy
change for some entropically driven formation of
PCCs, not always leading toward the free energy
minimization, that is due to propensity and propa-
gation of heterosynthons to replace homosynthons,
because of difference in energies of intra- and in-
termolecular forces that contribute the lattice en-
ergy. (29) This confirms the difference in the thermo-
dynamic stability between PCcs and PSs comparing
to their parent components and propose modeling for
their crystal structure prediction to offer designing
the accurate experimental crystallization screening
strategies. (30–32) Though the computed energies
of the crystals structures, ranged by the frequencies
of synthons appearing within the CSD, reveal that
at least 50% of the lattice energy is contributed by
heterosynthons and to a few strong H-bonds between
heterodymers and adjunct molecules, the higher en-
ergy value of surpamolecular synthon carboxylic
acid– pyridine(carboxylate/pyridinium, ionized cou-
pled moieties) for PSs for ∼10 kJ/mol, comparing
for carboxylic acid – pyridine (neutral pair) con-
firmed the proton transfer that distinguishes PSs
from PCCs. (30)Figure 2
FIGURE 2: Supramolecular homo- and hetero-
synthons in CSD(Cambridge Structural Database): 1 
Acid–Amide; 2 Acid–Pyridine; 3 Amide–Amide; 4 
Diphenylurea Hydrate; 5Hydroxyl–Acid; 6 
Hydroxyl–Pyridine
Although recent theoretical and high pressure studies
have shown that proton transfer in the pyridine-
formic acid system is dependent on the amount of
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formic acid present. (33, 34) Though the designing
the successful cocrystal screening experiments is
supported by strategies for selecting favorable co-
fomers, the derived models, based on supplementary
synthon strategy (35, 36), the criteria for shape and
polarity descriptors (37), lattice energy (38, 39) and
statistical analyses for knowledge-based PCCs pre-
diction based on prevalence of occurring hydrogen
bonds in relevant conformer structures in CSD (40,
41), so far lack accurate crystal structure prediction
(CSP) (42) . Recently, machine learning algorithm
based on the molecular descriptors were tested for
guiding the selection of coformers for a particu-
lar API in process of developing cocrystallization
screening experiments. (43). A Experimental data
generated by single crystal x-ray diffraction analyses
on the grown cocrystals of pharmaceutical com-
pound phloroglucinol reveal the three OH groups
of the phloroglucinol molecule are all involved in
hydrogen bonds acting always as donors with three
types of acceptor atoms: nitrogen (in most cases
aromatic N), oxygen (carbonylic or hydroxilic) and
O-atom from water molecules forming a cocrystals
depicted on Figure 3 (44) .
FIGURE 3: Mo fsof H-bonding interac ons 
between phloroglucinol and N-heterocycles (44)
Though the large organic cations and anions, even
when anions is conjugated base such it is sulfate,
phosphate or chloride of the particularly strong in-
organic acids, in PSs interact toward strong charge-
assisted H-bonds (45, 46), theirs exposed polar func-
tionalities with high hydration energy impact to addi-
tional stabilization toward the interaction with water.
Charge-assisted H-bonds were detected in molecular
salts of pyridoxine (vitamin B6) and hydroxylben-
zoic acid derivatives with strong antioxidant activity,
presented on Figure 4 . (47)
This uptake of water as solvent or from highly
humid atmosphere may cause either deliquescence
FIGURE 4: Mo fs of Charge-assisted H-bonds 
between pyridoxonium ca on andcarboxylated 
anions in molecular saltsof Pyridoxine (vitamin 
B6) (47)
of salt, forming form high concentrated solutions
unable to crystallize under ambient temperature and
humidity, or to form crystalline salts hydrates within
water polar molecules with metal cation cocrystal-
ize in stoichiometric ration along exposed crystal
faces. (48, 49) Calculated lower lattice energy for
majority of cocrystals then the values for the sum
of their components lattice energies, imply to higher
thermodynamic stability and more feasible cocrystal
formation. (30, 39, 50)
Conclusion and perspective for further research
on pharmaceutical crystalline solids
PCC and PSs offer the opportunities for beneficial
therapy outcomes if API cocrystalize with conform-
ers or salt formers that lead to formation of mul-
ticomponent crystals that structure influence alter-
nated particle habits and size, consequently that tune
their hydroscopicity, processability, thermodynamic
and photostability, and modulate both its thermody-
namic and kinetic solubility up to extent of plasma
concentration that suits the therapeutic index. (51)
The emergency for understanding solid-state control,
selection and properties in late stage of drug dis-
covery and NEC (New Chemical Entity) drug de-
velopment obeys Quality by Design (QbD) concept
that is proposed within to scientifically proven ICH
Q8(R2) guideline. (52) Machine learning concept,
based on the Artificial Neuron Networks (ANN) is
developed for prediction of solid state properties of
cocrystals (melting points, lattice energy and crystal
density). (53)
Engineering multidrug cocrystals (54) has become
viable platform for overcoming the drawbacks of
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conventional formulations for fixed-doses combina-
tion (FDC) such it is multi-drug resistance and ad-
verse and side effects. (55) Furthermore, the advan-
tage of formulating multidrug cocrystals should be
expected to attenuate or enhance the drug action syn-
ergistically by rational selection of combined drugs,
more convenient to get compliance and adherence in
therapy, to reduce the copayment cost for patients,
and to support the market exclusivity that, due to
patentable formulation, implies the improvement in
sales and profits for pharmaceutical companies. (54,
56).
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